These 3 sectors could be in focus next year in Washington — no matter who wins on Tuesday

The 2026 campaign has featured bipartisan calls for action on pharmaceuticals, the housing market, and AI data centers, a sign that this trio of sectors may be in focus in Washington no matter which party prevails on Tuesday.

The critical comments are especially notable coming from Republicans as the campaign enters its final days. Democratic rhetoric about reining in big business is nothing new, but the GOP's focus indicates both an increased willingness within the party to adopt a populist stance and a potential openness to strike deals next year in the new power-sharing landscape.

And the high likelihood that Democrats will win control of at least one chamber of Congress could elevate these issues — with or without President Trump's support.

Democrats are now strongly favored to win a majority in the House, with a Harvard election forecasting model pegging the odds on Friday at 94%. The Senate is less clear, but its 60-vote threshold means any action next year there will require bipartisan buy-in.

That is always a heavy lift in today's increasingly polarized Washington, but the housing issue provided proof of concept this year, after a major piece of legislation passed and became law despite Trump's refusal to sign it.

MINNEAPOLIS, MINNESOTA - OCTOBER 28: Signage directs people outside an early voting polling place at Lynnhurst Recreation Center on October 28, 2026 in Minneapolis, Minnesota. Minnesota residents are voting for successors to Gov. Tim Walz and Sen. Tina Smith (D-MN) among other races. (Photo by Stephen Maturen/Getty Images)
Signage directs people outside an early voting polling place on Oct. 28 in Minneapolis. (Stephen Maturen/Getty Images) · Stephen Maturen via Getty Images

The coming year is likely to feature "meaningful opportunities and risks for key sectors," Stifel chief Washington policy strategist Brian Gardner wrote in a recent note to clients.

He suggested tech companies and data center operators will face challenging headlines, but "risks are low that Congress would pass heavy-handed legislation ... we expect that it would enact a light-touch framework."

He added that the healthcare sector could be in closer focus, writing "a change in power on Capitol Hill could be seen as a negative for pharmaceuticals as Democrats and the White House might agree to further regulate drug prices."

Read more: What is a healthcare FSA? How to save on medical costs.

Pharmaceuticals are a prime example of this dynamic, with a high volume of campaign-trail rhetoric coming from both parties. 

GOP Senate hopeful Mike Rogers of Michigan cut an ad saying "the pharmaceutical companies are ripping American families off," while Iowa Republican Ashley Hinson is pledging to "put the squeeze on Big Pharma." 

Screengrab of a campaign ad from Mike Rogers.
A still from a campaign advertisement from Republican Mike Rogers of Michigan.

That means — regardless of whether Rogers, Hinson, or their Democratic opponents win next Tuesday — openly critical lawmakers will head to Washington amid prominent areas of bipartisan agreement on regulating drug companies.